The 2021 version of the medical insurance catalogue is adjusted, and the price of AbbVie's AML innovative drug is reduced by 18.3% to "pave the way" for medical insurance negotiations

June 30, 2021-This is the draft of the "2021 National Medical Insurance Drug Catalog Adjustment Work Plan" announced by the National Medical Insurance Administration, which clearly mentions the latest launch of innovative drugs that can be included in the new round of this year's medical insurance catalog dynamic adjustment Time

Compared with the "soul bargaining" of the previous two years, the public this year is more concerned about whether the above batch of clinically needed new drugs and good drugs can be included in the first time to benefit patients; whether the needs of special groups such as the elderly and children can be obtained Further care

Only half a year after listing, Vinacola took the initiative to cut the price by 18.

Recently, when the editor of Sina Pharmaceuticals visited the store, it was accidentally discovered that the milestone new drug in the field of acute myeloid leukemia (AML), which was only approved for marketing in December 2020-Venacola tablets (trade name: WeiKeLai), its 100mgⅹ14 tablets The price of a single box of specifications quietly dropped from the original 5950 yuan to 4860 yuan, a price cut of 18.

Only the latest 100mg packaging box

On January 3, 2020, AbbVie submitted to the China National Medical Products Administration a marketing application for Veneclax tablets for the treatment of acute myeloid leukemia, and it went on the market through the priority review channel in less than a year

AML is a kind of cancer caused by the abnormal proliferation of primitive and immature myeloid cells in the bone marrow and peripheral blood.

The State Food and Drug Administration gave Venecla Tablets priority review, mainly because acute myeloid leukemia seriously endangers the lives of elderly patients, and there is currently no effective treatment

As AbbVie's "ace" in the field of hematology and tumors and the exclusive new drug in this field, there is no urgency to reduce the price of Veneclax tablets that have been on the market for more than half a year in China

China has carried out the adjustment of the medical insurance catalog for four consecutive years, including a total of 433 new and good drugs

After 30 years of sharpening a sword, AML has entered the era of targeted therapy

As AbbVie's exclusive blockbuster product, the Venecla film was launched in China at the end of last year, which is well received by the public

There are 20 members of the BCL-2 gene family, which are involved in regulating intracellular apoptosis and balancing cell survival and death

In April 2016, Vinacola tablets were finally approved by the US FDA for the treatment of chronic lymphocytic leukemia (CLL) caused by chromosome 17p deletion, becoming the world's first BCL-2 inhibitor approved for marketing; November 2018, Obtained accelerated FDA approval for the treatment of newly diagnosed adult AML patients who are ≥75 years of age or who have complications that cannot use intensive induction chemotherapy

It is worth mentioning that after seeing the excellent performance of Veneclax tablets in the treatment of acute myeloid leukemia, the National Medical Products Administration of China also gave AbbVie the green channel treatment for rapid review

Professor Wang Jianxiang, vice president of the Institute of Hematology of the Chinese Academy of Medical Sciences and the Deputy Dean of the Hospital of Hematology, believes that the entry of Vinacola tablets in China has not only broken the deadlock of no breakthrough innovative therapies in the field of AML treatment in recent decades, but also brought the treatment of AML into China.